Kenacort Retard (Triamcinolone Acetonide)

Triamcinolone acetonide binds to glucocorticoid receptors inside cells, forming a complex that moves into the nucleus and modifies gene expression. This suppresses the production of inflammatory cytokines, inhibits enzymes that generate prostaglandins, and reduces the migration of immune cells, thereby decreasing inflammation and pain.

The dose of Kenacort Retard is determined by the prescribing healthcare professional based on the specific indication, patient characteristics, and treatment goals. Dosage may vary for intra‑articular versus intralesional administration, and the prescriber will provide the appropriate regimen.

Kenacort Retard should be used in pregnancy only if clearly needed, as corticosteroids can cross the placenta and may affect fetal development. Caution is also advised during breastfeeding because the drug can be excreted in milk. The prescriber should evaluate the risk‑benefit ratio for each patient.

To order Kenacort Retard, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details and any necessary import documentation.

Kenacort Retard contains triamcinolone acetonide, a potent intermediate‑acting corticosteroid with a relatively long duration of action when administered as a suspension. Compared with shorter‑acting agents like hydrocortisone, it provides prolonged anti‑inflammatory effects, reducing the need for frequent injections. Its potency is similar to methylprednisolone but with a distinct release profile.

Kenacort Retard should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and avoid freezing. Follow any additional handling instructions provided by the manufacturer to maintain product stability.

Kenacort Retard is administered by a qualified healthcare professional as an injection. It can be given intra‑articularly into a joint space, intralesionally into skin lesions, or intramuscularly, depending on the therapeutic indication. Proper aseptic technique and appropriate anatomical guidance are essential for safe administration.

Serious risks include adrenal suppression with prolonged use, osteonecrosis of bone, and increased susceptibility to severe infections. Patients should be monitored for signs of systemic corticosteroid effects, and the drug should be used cautiously in individuals with a history of infection, osteoporosis, or endocrine disorders.

Kenacort Retard is contraindicated in patients with known hypersensitivity to triamcinolone acetonide or any component of the formulation. It should also be avoided in individuals with active systemic infections, uncontrolled diabetes, or those receiving live vaccines, unless the benefits clearly outweigh the risks.